Interleukin-1α-mediated promotion of long-term alloengraftment and short-term neutrophil expansion does not require the presence of either donor or host T cells

Transplantation

Volumn 62, Issue 5, 1996, Pages 636-642

  Vallera, Daniel A ^a,b   Taylor, Patricia A ^b   Widmer, Michael B ^c   Blazar, Bruce R ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIV OF MINNESOTA HOSP AND CLINIC   (United States)

^c AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY CD3; OKT 4; RECOMBINANT INTERLEUKIN 1ALPHA;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW TRANSPLANTATION; COMBINED IMMUNODEFICIENCY; CONTROLLED STUDY; GRAFT REJECTION; INTRAPERITONEAL DRUG ADMINISTRATION; LYMPHOCYTE DEPLETION; MOUSE; NEUTROPHIL; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE; THYMECTOMY; WHOLE BODY RADIATION;

EID: 0029788349     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199609150-00017     Document Type: Article

References (42)

1. Blazar BR, Widmer MB, Cosman D, Sassenfeld HM, Vallera DA. Improved survival and leukocyte reconstitution without detrimental effects on engraftment in murine recipients of human recombinant granulocyte colony-stimulating factor following transplantation of T cell depleted histoincompatible bone marrow. Blood 1989; 74: 2264.
2. Blazar BR, Widmer MB, Soderling CCB, Gillis S, Vallera DA. Enhanced survival but reduced engraftment in murine recipients of recombinant granulocyte/macrophage colony-stimulating factor following transplantation of T-cell depleted histoincompatible bone marrow. Blood 1988; 72: 1148.
3. Blazar BR, Aukermann SL, Vallera DA. Effect of recombinant human macrophage colony-stimulating factor in irradiated murine recipients of T cell depleted allogeneic or non-depleted syngeneic bone marrow transplants. Blood 1992; 79: 1636.
4. Blazar BR, Widmer MB, Taylor PA, Vallera DA. Promotion of murine marrow alloengraftment and hematopoietic recovery across the major histocompatibility barrier by administration of recombinant human interleukin-1. Blood 1992; 80: 1614.
5. Dinarello CA. Interleukin-1 and interleukin-1 antagonism. Blood 1991; 77: 1627.
6. Oppenheim JJ, Neta R, Tiberghien P, Gress R, Kenny J, Longo DL. Interleukin-1 enhances survival of lethally irradiated mice treated with allogeneic bone marrow cells. Blood 1989; 74: 2257.
7. Antin JH, Ferrara JLM. Cytokine dysregulation and acute graft-versus-host disease. Blood 1992; 80: 2964.
8. Weisdorf D, Katsanis E, Verfaillie C, et al. Interleukin-1 administered after autologous transplantation: a phase I/II clinical trial. Blood 1994; 84: 2044.
9. Vallera DA, Blazar BR. T cell depletion for graft-versus-host disease prophylaxis: a perspective on engraftment in mice and humans. Transplantation 1989; 47: 751.
10. Simic MM, Stosic GS. The dual role of interleukin 1 in lectin-induced proliferation of T cells. Folia Biol (Praha) 1985; 31: 410.
11. Vallera DA, Soderling CCB, Carlson GJ, Kersey JH. Bone marrow transplantation across major histocompatibility barriers in mice. The effect of elimination of T cells from donor grafts by treatment with monoclonal Thy 1.2 plus complement or antibody alone. Transplantation 1981; 31: 218.
12. Blazar BR, Thiele DL, Vallera DA. Pretreatment of murine donor grafts with L-leucyl-L-leucine methyl ester: elimination of graft-versus-host disease without detrimental effects on engraftment. Blood 1990; 75: 798.
13. Dialynas DM, Quan ZS, Wall KA, et al. Characterization of the murine T cell surface molecule, designated L3T4, identified by mAb GK1.5. J Immunol 1983; 131: 2445.
14. Sarmiento M, Dialynas DP, Lancki DW, et al. Cloned T lymphocytes and monoclonal antibodies as probes for cell surface molecules active in T-cell mediated cytolysis. Immunol Rev 1982; 68: 135.
15. Lowenthal JW, MacDonald HR. Binding and internalization of interleukin-1 by T cells: Direct evidence for high- and low-affinity classes of interleukin-1 receptor. J Exp Med 1986; 164: 1060.
16. March CJ, Mosley B, Larsen A, et al. Cloning, sequence and expression of two distinct human interleukin-1 complementary DNAs. Nature 1985; 315: 641.
17. Blazar Br, Hirsch R, Gress RE, Carroll SF, Vallera DA. In vivo administration of anti-CD3 monoclonal antibodies or immunotoxins in murine recipients of allogeneic T cell depleted marrow for the promotion of engraftment. J Immunol 1991; 147: 1492.
18. Jansen B, Vallera DA, Jaszcz WB, Nguyen D, Kersey J. Successful treatment of human acute T-cell leukemia in scid/scid mice using anti-CD7-deglycosylated ricin a-chain immunotoxin DA7. Cancer Res 1992; 52: 1314.
19. Blazar BR, Widmer MB, Soderling CCB, et al. Augmentation of donor bone marrow engraftment in histoincompatible murine recipients by granulocyte macrophage colony-stimulating factor. Blood 198; 871: 320.
20. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163.
21. Murphy JM, Kumar V, Cope JC, Bennet M. An absence of T cells in murine bone marrow allografts leads to an increased susceptibility to rejection by natural killer cells and T cells. J Immunol 1990; 144: 3305.
22. Storb R, Nash RA, Schuening FG, et al. Failure of interleukin-1 and granulocyte-macrophage colony-stimulating factor to enhance allogeneic marrow engraftment and survival in irradiated dogs. Blood 1995; 86: 833.
23. Galy AHM, Dinarello CA, Kupper TS, Hadden JW. Effects of cytokines on human thymic epithelial cells to produce cytokines. Cell Immunol 1990; 129: 161.
24. Stanley ER, Bartocci A, Patinkin D, Tosendall M, Bradley TR. Regulation of very primitive mulipotent hemopoietic cells by hemopoietin-1. Cell 1986; 45: 667.
25. Williams DE, Broxmeyer HE. Interleukin-1α enhances the in vitro survival of purified murine granulocyte-macrophage progenitor cells in the absence of colony-stimulating factors. Blood 1988; 72: 1608.
26. Fibbe WE, Van Damme J, Billiau A, et al. Interleukin-1 (22-K factor) induces release of granulocyte-macrophage colony-stimulating activity from human mononuclear phagocytes. Blood 1986; 68: 1316.
27. Moreb R, Zucali JR. Role of interleukin-1 in 4-hydroperoxycyclophosphamide toxicity to bone marrow progenitor cells: a review. Biotherapy 1989; 1: 273.
28. Moreb JI, Zucali JR, Gross MA, Weiner RS. Protective effects of IL-1 on human hematopoietic progenitor treated in vitro with 4-hydroperoxycyclophosphamide. J Immunol 1989; 142: 1937.
29. Castelli MP, Black PL, Schneider M, Pennington R, Abe F, Talmadge JE. Protective, restorative, and therapeutic properties of recombinant human IL-1 in rodent models. J Immunol 1988; 140: 3830.
30. Johnson CS, Keckler DJ, Topper MI, Braunschweiger PG, Furmanski P. In vivo hematopoietic effects of recombinant interleukin-1α in mice: stimulation of granulocytic, megakaryocytic, and early erythroid progenitors, suppression of late-stage erythropoiesis and reversal of erythroid suppression with erythropoietin. Blood 1989; 73: 678.
31. Neta R, Sztein MB, Oppenheim JJ, Gillis S, Douches SD. The in vivo effects of interleukin-1. I. Bone marrow cells are induced to cycle after administration of interleukin-1. J Immunol 1987; 139: 1861.
32. Schwartz GN, MacVittie TJ, Vigneulle RM, et al. Enhanced hematopoietic recovery in irradiated mice pretreated with interleukin-1 (IL-1). Immunopharmacol Immunotoxicol 1987; 9: 371.
33. Moreb J, Zucali JR, Weiner RS. The role of interleukin 3 and interleukin 6 in the protection from 4-hydroperoxycyclophosphamide and the proliferation of early human hematopoietic progenitor cells. Exp Hematol 1989; 17: 1022.
34. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996; 87: 2095.
35. Rafii S, Shapiro F, Rimarachin J, et al. Isolation and characterization of human bone marrow microvascular endothelial cells: hematopoietic progenitor cell adhesion. Blood 1994; 84: 10.
36. Bagby GC Jr. Interleukin-1 and hematopoiesis. Blood Rev 1989; 3: 152.
37. Brugger W, Mocklin W, Heimfeld S, Berenson RJ, Mertelmann R, Kanz L. Ex vivo expansion for enriched peripheral blood CD34+ progenitor cells by stem cell factor, interleukin-1β, IL-6, IL-3, interferon-γ, and erythropoietin. Blood 1993; 81: 2579.
38. Heimfeld S, Hudak S, Weissman I, Rennick D. The in vitro response of phenotypically defined mouse stem cells and myeloerythroid progenitors to a single or multiple growth factors. Proc Natl Acad Sci USA 1991; 88: 9902.
39. Neta R, Vogel SN, Plocinski JM, et al. In vivo modulation with anti IL-1 receptor (p80) antibody 35F5 of the response to IL-1. Blood 1990; 76: 57.
40. Henricson BE, Neta R, Vogel SN. An interleukin-1 receptor antagonist blocks lipopolysaccharide-induced colony stimulating factor production and early endotoxin tolerance. Infect Immun 1991; 59: 1188.
41. Katsanis E, Weisdorf DJ, Xu Z, Dancisak BB, Halet ML, Blazar BR. Infusions of interleukin-1 after autologous transplantation for Hodgkin's disease and non-Hodgkin's lymphoma induce effector cells with antilymphoma cytolytic activity. J Clin Immunol 1994; 14: 205.
42. Blazar Br, Soderling CCB, Koo GC, Vallera DA. Absence of a facilitory role for NK 1.1 positive donor cells in engraftment across a major histocompatibility barrier in mice. Transplantation 1988; 45: 876.